Assignee
CELLECTIS
FR·80 granted patents·84 pending applications·457 citations·filing 2002–2025
Top patents by PatentIndex Score
164 records- 0198US10584352B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2018·Granted Mar 10, 2020·21 cites·20 claims
- 0298US9855297B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2016·Granted Jan 2, 2018·50 cites·17 claims
- 0397US10870864B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Dec 22, 2020·4 cites·18 claims
- 0497US9890393B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2014·Granted Feb 13, 2018·38 cites·3 claims
- 0596US11077144B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted Aug 3, 2021·7 cites·17 claims
- 0696US9944702B2CD33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·29 cites·29 claims
- 0795US10286007B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2017·Granted May 14, 2019·12 cites·18 claims
- 0895US9944709B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·21 cites·19 claims
- 0995US7897372B2I-CreI meganuclease variants with modified specificity, method of preparation and uses thereofCELLECTIS·Filed 2006·Granted Mar 1, 2011·42 cites·54 claims
- 1095US7842489B2Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereofCELLECTIS·Filed 2010·Granted Nov 30, 2010·63 cites·7 claims
- 1194US11274316B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2021·Granted Mar 15, 2022·2 cites·5 claims
- 1294US10874693B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2014·Granted Dec 29, 2020·7 cites·11 claims
- 1393US10752684B2ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Aug 25, 2020·12 cites·10 claims
- 1493US10196608B2Method for in situ inhibition of regulatory T cellsCELLECTIS·Filed 2015·Granted Feb 5, 2019·8 cites·16 claims
- 1592US10836998B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2015·Granted Nov 17, 2020·5 cites·26 claims
- 1691US10759868B2Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Sep 1, 2020·6 cites·8 claims
- 1791US10363270B2Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapyCELLECTIS·Filed 2017·Granted Jul 30, 2019·6 cites·7 claims
- 1891US10316101B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Jun 11, 2019·11 cites·20 claims
- 1990US10426795B2Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cellsCELLECTIS·Filed 2013·Granted Oct 1, 2019·8 cites·17 claims
- 2089US11186824B2Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patientsCELLECTIS·Filed 2016·Granted Nov 30, 2021·4 cites·22 claims
- 2189US10239948B2Method of engineering multi-input signal sensitive T cell for immunotherapyCELLECTIS·Filed 2014·Granted Mar 26, 2019·16 cites·9 claims
- 2289US2024309397A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 2388US10709775B2Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivationCELLECTIS·Filed 2016·Granted Jul 14, 2020·7 cites·15 claims
- 2488US10378026B2RNA based method to obtain stably integrated retroviral vectorsCELLECTIS·Filed 2014·Granted Aug 13, 2019·6 cites·11 claims
- 2588US10006052B2Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereofCELLECTIS·Filed 2014·Granted Jun 26, 2018·17 cites·14 claims
- 2687US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 2787US10342829B2Multi-chain chimeric antigen receptor and uses thereofCELLECTIS·Filed 2013·Granted Jul 9, 2019·6 cites·6 claims
- 2886US12252699B2Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2023·Granted Mar 18, 2025·0 cites·12 claims
- 2986US11891614B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2020·Granted Feb 6, 2024·1 cites·16 claims
- 3086US10517896B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Dec 31, 2019·2 cites·19 claims
- 3185US12577581B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2022·Granted Mar 17, 2026·0 cites·9 claims
- 3285US11466291B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2017·Granted Oct 11, 2022·4 cites·27 claims
- 3385US11014989B2Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapyCELLECTIS·Filed 2016·Granted May 25, 2021·2 cites·24 claims
- 3485US10472613B2Method for modulating car-induced immune cells activityCELLECTIS·Filed 2015·Granted Nov 12, 2019·6 cites·29 claims
- 3583US10113162B2Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genesCELLECTIS·Filed 2014·Granted Oct 30, 2018·6 cites·13 claims
- 3682US2022177914A1Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cellsCELLECTIS·Filed 2022·Application pending·0 cites
- 3782US2025188483A1Methods for non-transgenic genome editing in plantsCELLECTIS·Filed 2024·Application pending·0 cites
- 3881US10087453B2Modified diatoms for biofuel productionCELLECTIS·Filed 2014·Granted Oct 2, 2018·4 cites·20 claims
- 3980US12391933B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2023·Granted Aug 19, 2025·0 cites·15 claims
- 4080US9365864B2Meganuclease recombination systemCELLECTIS·Filed 2013·Granted Jun 14, 2016·3 cites·19 claims
- 4179US11674155B2Sequential gene editing in primary immune cellsCELLECTIS·Filed 2022·Granted Jun 13, 2023·0 cites·17 claims
- 4279US11498971B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2019·Granted Nov 15, 2022·1 cites·26 claims
- 4379US11414674B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Aug 16, 2022·0 cites·10 claims
- 4478US2023357719A1Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 4577US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 4677US11007224B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted May 18, 2021·0 cites·10 claims
- 4776US10988541B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2018·Granted Apr 27, 2021·1 cites·18 claims
- 4876US2023287454A1Sequential gene editing in primary immune cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 4976US2024182565A1Cd33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 5075US11959091B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Apr 16, 2024·0 cites·21 claims
Showing the top 50 of 164 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CELLECTIS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →